Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-IT101 in Advanced Non-Small Cell Lung Cancer
NCT07830342Phase 1Recruiting
- Sponsor
- Huasai Biomedicine
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-IT101 in non-small cell lung cancer (NSCLC), sponsored by Huasai Biomedicine. Primary endpoints: Safety and tolerability of HS-IT101 injection at 2 years and Preliminary efficacy of HS-IT101 injection at 2 years. Started Sep 2026; status: recruiting.
02
Drugs
HS-IT101
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07830342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830342.